Ventyx Biosciences (VTYX) received a strategic investment of $27 million from Sanofi, which will be used to support the company’s ongoing operations and advance its investigational drug, VTX3232, for neuroinflammatory and neurodegenerative diseases. In exchange, Sanofi gains exclusive rights to negotiate certain rights related to VTX3232’s clinical programs.